Preclinical Safety: Thymic Lesions in rasH2 Transgenic Mice

Since 2003, the rasH2 transgenic mice model has served as a cornerstone for evaluating the carcinogenic potential of novel pharmaceuticals. These 26-week assays offer a rapid alternative to traditional two-year studies. However, accurate interpretation of these studies depends on a comprehensive understanding of spontaneous background lesions. A recent analysis of nearly 4,000 control animals has provided significant updates on the incidence of thymic epithelial hyperplasia and neoplastic findings in this strain.

Incidence Rates of Thymic Epithelial Hyperplasia

The study reviewed pathology data from sixty-three carcinogenicity studies conducted between 2012 and 2024. Researchers identified a notable increase in the incidence of epithelial hyperplasia compared to previously published literature. Specifically, female rasH2 transgenic mice showed a 7.4% incidence rate, while males exhibited a 3.4% rate. Notably, the study used pan-cytokeratin immunohistochemistry to confirm the epithelial origin of these proliferative changes. These benchmarks are vital for toxicologic pathologists to distinguish between spontaneous findings and treatment-related effects.

Emergence of Malignant Thymoma

Furthermore, the data documented the first known occurrences of malignant thymoma in this mouse strain. While benign thymomas appeared at higher-than-expected rates (1.8% in females and 0.7% in males), the identification of malignant variants marks a significant diagnostic update. These malignant lesions occurred more frequently in females at a rate of 1%. Consequently, this new historical control data improves the reliability of safety assessments during drug development. Pathologists must remain aware of these rare but spontaneous neoplastic occurrences when reviewing thymus sections.

FAQs

Why is the rasH2 transgenic mice model preferred for carcinogenicity testing?

This model allows for a 6-month study duration rather than 2 years because it is highly sensitive to both genotoxic and non-genotoxic carcinogens due to the human c-Ha-ras transgene.

How does this study impact drug safety evaluations?

Pharmaceutical researchers and regulatory bodies rely on these global standards to interpret preclinical data. Accurate background incidence rates prevent the false attribution of spontaneous lesions to a drug candidate.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Refer to the latest local and national guidelines for clinical practice.

References

Mishra S et al. Thymic Epithelial Hyperplasia and Thymoma in Control rasH2 Transgenic Mice From 26-Week Carcinogenicity Assays. Toxicol Pathol. 2026 Apr 05. doi: 10.1177/01926233261429439. PMID: 41936107.

Paranjpe MG et al. Incidence of Spontaneous Non-Neoplastic Lesions in Transgenic CBYB6F1-Tg(HRAS)2Jic Mice. Toxicol Pathol. 2013;41(4):624-633.

Nambiar PR et al. Spontaneous Findings in the Tg.rasH2 Mouse: A 10-Year Retrospective Review. Toxicol Pathol. 2014;42(1):198-208.